Erratum: Leptonic Decay of the ϒ(1S) Meson at Third Order in QCD [Phys. Rev. Lett. 112, 151801 (2014)].

This corrects the article DOI: 10.1103/PhysRevLett.112.

Feasibility of real-time motion management with helical tomotherapy.

Purpose: This study investigates the potential application of image-based motion tracking and real-time motion correction to a helical tomotherapy system.

Methods: A kV x-ray imaging system was added to a helical tomotherapy system, mounted 90 degrees offset from the MV treatment beam, and an optical camera system was mounted above the foot of the couch. This experimental system tracks target motion by acquiring an x-ray image every few seconds during gantry rotation.

Enhanced Electromagnetic Corrections to the Rare Decay B_{s,d}→μ^{+}μ^{-}.

We investigate electromagnetic corrections to the rare B-meson leptonic decay B_{s,d}→μ^{+}μ^{-} from scales below the bottom-quark mass m_{b}. Contrary to QCD effects, which are entirely contained in the B-meson decay constant, we find that virtual photon exchange can probe the B-meson structure, resulting in a "nonlocal annihilation" effect. We find that this effect gives rise to a dynamical enhancement by a power of m_{b}/Λ_{QCD} and by large logarithms.

Next-to-Next-to-Next-to-Leading Order QCD Prediction for the Top Antitop S-Wave Pair Production Cross Section Near Threshold in e(+)e(-) Annihilation.

We present the third-order QCD prediction for the production of top antitop quark pairs in electron-positron collisions close to the threshold in the dominant S-wave state. We observe a significant reduction of the theoretical uncertainty and discuss the sensitivity to the top quark mass and width.

Leptonic decay of the ϒ(1S) meson at third order in QCD.

We present the complete next-to-next-to-next-to-leading order short-distance and bound-state QCD correction to the leptonic decay rate Γ(ϒ(1S)→ℓ+ℓ-) of the lowest-lying spin-1 bottomonium state. The perturbative QCD prediction is compared to the measurement Γ(ϒ(1S)→e+e-)=1.340(18)  keV.

Outcomes of a prospective multi-center trial of a second-generation composite mesh for open ventral hernia repair.

Purpose: Composite mesh prostheses incorporate properties of multiple materials for use in open ventral hernia repair (OVHR). This study examines clinical outcomes in patients who underwent OVHR with a polypropylene/expanded polytetrafluoroethylene (ePTFE) composite graft containing a novel polydioxanone (PDO) absorbable ring to facilitate placement and graft positioning.

Methods: Data were prospectively collected on consecutive patients undergoing OVHR using a synthetic composite mesh.

Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: results of a randomized, placebo-controlled trial.

Introduction: The prevalence of erectile dysfunction (ED) is increased in men with metabolic syndrome compared with the general population.

Aim: The aim of this study was to evaluate the efficacy and safety of vardenafil vs. placebo in men who had ED and metabolic syndrome.

Improvement in sexual quality of life of the female partner following vardenafil treatment of men with erectile dysfunction: a randomized, double-blind, placebo-controlled study.

Introduction: Erectile dysfunction (ED) impacts on both members of the couple. Female partners of men with ED are more likely to report reduced sexual quality of life than women whose partners do not have ED.

Aim: To assess vardenafil efficacy in men with ED and determine the effects of treatment on their female partner's sexual quality of life.

The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction.

Aims: The aim of this study was to investigate the efficacy and safety of 10 mg vardenafil orodispersible tablet (ODT) vs. placebo in a general population of men with erectile dysfunction (ED).

Methods: This was a double-blind, multicentre, randomised, parallel-group, placebo-controlled study conducted at 35 centres in Australia, Canada, Mexico and the United States.

Acoustic pressure wound therapy to debride unstageable pressure ulcers in the acute care setting: a case series.

As of October 1, 2008, prompt identification and accurate staging of pressure ulcers present on admission to acute care hospitals became essential for Medicare reimbursement. In short, Medicare will no longer cover the added costs associated with care of Stage III and Stage IV pressure ulcers not present on admission; such ulcers will be classified as hospital-acquired conditions that could reasonably be prevented with application of evidence-based guidelines. Unstageable pressure ulcers present a particular challenge under the new policy.

A double-blind placebo-controlled discontinuation study of zuclopenthixol for the treatment of aggressive disruptive behaviours in adults with mental retardation - secondary parameter analyses.

Introduction: Earlier studies showed risperidone to be effective in the treatment of aggression and self-injurious behaviour in adults with mental retardation but also having adverse side effects. This study was conducted to evaluate the effects of zuclopenthixol withdrawal.

Methods: After open treatment with zuclopenthixol (n=49) responders were randomly assigned to continue (n=19) or discontinue (n=20) zuclopenthixol treatment during a 12-week double-blind, placebo-controlled period.

Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study.

Background: Phosphodiesterase (type) 5 (PDE5) inhibitors are currently administered on demand for treatment of erectile dysfunction (ED). Once-daily dosing has been suggested to benefit patients.

Objective: To determine whether daily vardenafil use provides added clinical benefits to patients compared with on-demand dosing.

A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Introduction: Benign prostatic hyperplasia (BPH) is associated with bothersome lower urinary tract symptoms (LUTS) and reduced patient quality of life (QoL). Phosphodiesterase (type) 5 (PDE5) inhibitors such as vardenafil are commonly used for the treatment of erectile dysfunction (ED), but have also been shown to improve the symptoms of BPH. This randomised, double-blind, placebo-controlled study investigated the effects of vardenafil on LUTS and QoL in men with BPH/LUTS, with or without concomitant ED.

Zuclopenthixol in adults with intellectual disabilities and aggressive behaviours: discontinuation study.

We investigated the effects of zuclopenthixol on aggressive behaviour in patients with intellectual disabilities by randomly withdrawing it after a 6-week period of open treatment. Of the 49 patients responding to the treatment, 39 took part in a randomised withdrawal trial. The placebo subgroup (n=20) showed more aggressive behaviour as indicated by outcomes observed by external raters on the Modified Overt Aggression Scale than did the continuing subgroup (n=19).

The COUPLES-project: a pooled analysis of patient and partner treatment satisfaction scale (TSS) outcomes following vardenafil treatment.

Objective: To assess the influence of vardenafil on treatment satisfaction in men with erectile dysfunction (ED) and their female partners.

Patients And Methods: This was a pooled analysis of three randomized, double-blind, placebo-controlled, 12-week studies of flexible-dose vardenafil vs placebo, in men with ED for >/=6 months (n = 788) and their untreated female partners. Measures of efficacy included the Treatment Satisfaction Scale (TSS), International Index of Erectile Function, Erectile Function domain (IIEF-EF), and Sexual Encounter Profile (SEP) questions 2 and 3 (SEP-2, 'Were you able to insert your penis into your partner's vagina?'; and SEP-3, 'Did your erection last long enough for you to have sexual intercourse?').

The efficacy of hydrotalcite compared with OTC famotidine in the on-demand treatment of gastroesophageal reflux disease: a non-inferiority trial.

Background: Antacids and gastric acid inhibitors are effective in the self-treatment of gastroesophageal reflux disease (GERD). The aim was to investigate onset of action of the antacid hydrotalcite compared with the OTC H2-receptor antagonist famotidine in patients suffering from heartburn.

Material/methods: A total of 53 patients with endoscopically diagnosed GERD grade 0-1 took part in this open, randomized, parallel-group comparison trial: 26 patients received a single dose of 1000 mg hydrotalcite and 27 patients a single dose of 10 mg famotidine on the occasion of a symptomatic reflux episode.

Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.

Rationale: Flupentixol (FLX) has been used as a neuroleptic for nearly 4 decades. In vitro data show comparable affinity to dopamine D(2), D(1) and 5-HT(2A) receptors and recently, FLX showed to be not inferior to risperidone in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.

Objectives: To assess in vivo receptor occupancy (RO) in patients clinically treated with FLX (n = 13, 5.

Enhanced electroweak penguin amplitude in B-->VV decays.

We discuss a novel electromagnetic penguin contribution to the transverse helicity amplitudes in B decays to two vector mesons, which is enhanced by two powers of mB/Lambda relative to the standard penguin amplitudes. This leads to unique polarization signatures in penguin-dominated decay modes such as B-->rhoK* similar to polarization effects in the radiative decay B-->K*gamma and offers new opportunities to probe the magnitude and chirality of flavor-changing neutral current couplings to photons.

Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial.

Introduction: Vardenafil, a potent and selective oral PDE5 inhibitor, is efficacious and generally well-tolerated in men with erectile dysfunction (ED). Of considerable interest to patients and physicians is an understanding of the time required after dosing to attain penile erection sufficient for successful sexual intercourse.

Aim: To determine the earliest time to onset of action of vardenafil 10 and 20 mg leading to successful intercourse compared to placebo in men with ED.

Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.

Objective: To investigate the efficacy and tolerability of almotriptan 12.5 mg in migraine patients who respond poorly to sumatriptan 50 mg.

Background: Poor response to sumatriptan therapy for acute migraine attacks has been documented in the literature, but few controlled trials have investigated the efficacy of an alternative triptan in this subgroup of patients.

Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.

Objective: To investigate the efficacy and tolerability of almotriptan 12.5 mg in migraine patients who respond poorly to sumatriptan 50 mg.

Background: Poor response to sumatriptan therapy for acute migraine attacks has been documented in the literature, but few controlled trials have investigated the efficacy of an alternative triptan in this subgroup of patients.

Efficacy of vardenafil in men with erectile dysfunction: a flexible-dose community practice study.

Objective: To determine the efficacy and tolerability of flexible dosing with vardenafil in a broad population of men with erectile dysfunction (ED).

Methods: 10-week, open-label, flexible-dose study starting with vardenafil 10 mg, titrating to 5 mg or 20 mg at weeks 2 and 6 based on efficacy and tolerability, set in 78 community practice centers in Germany and France. Participants comprised 398 men aged > or =18 years with ED.

Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction.

This randomised, double-blind study assessed the long-term efficacy and tolerability of vardenafil 10 and 20 mg in men with erectile dysfunction (ED). A total of 566 men who completed an initial 12-month treatment period entered a 12-month extension. In these men, both doses of vardenafil produced improvement in scores for the 'erectile function' Domain of the International Index of Erectile Function, evident from week 4 and maintained through 2 years.